AgomAb Therapeutics
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that can potentially restore organ function in patients with fibrotic, inflammatory, autoimmune, and degenerative diseases. The company is focusing on biologically validated pathways, such as Transforming Growth Factor β and Hepatocyte Growth Factor, and leveraging specialized capabilities in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline across multiple fibrotic conditions, end-to-end research and development expertise, a successful business development track record, and a robust investor base.
Tech Stack (23 technologies)
Frequently Asked Questions
What technologies does AgomAb Therapeutics use?+
AgomAb Therapeutics uses 23 technologies including Contact Form 7, Modernizr, MonsterInsights.
What industry is AgomAb Therapeutics in?+
AgomAb Therapeutics operates in the Biotechnology industry.
Where is AgomAb Therapeutics based?+
AgomAb Therapeutics is headquartered in Belgium.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026